Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
It is expected that the upcoming World Health Organisation's (WHO) annual assembly will be dominated this year by the emergence and spread of the new influenza virus H1N1 (swine flu).
Scientists at Baylor Institute for Immunology Research (BIIR) in Dallas, part of Baylor Research Institute (BRI) and the Baylor Health Care System, announced today that they received a renewal of a multi-million dollar grant from the National Institutes of Health (NIH) to design new vaccines to prevent influenza - including swine flu (H1N1).
Researchers at the University of Rochester have developed a mathematical model to predict immune responses to infection with influenza A viruses, including novel viruses such as the emergent 2009 influenza A (H1N1). This model examines the contributions of specific sets of immune cells in fighting influenza A virus.
Pregnant women and newborns are at greatest risk in a flu epidemic, but more planning must be done to ensure that they receive priority treatment should an outbreak occur, according to a University of Pittsburgh Medical Center (UPMC) and University of Pittsburgh study.
The latest update (# 26) from the World Health Organisation (WHO) reports that as of the 12th of May 2009, 30 countries have officially reported 5,251 cases of influenza A (H1N1) infection.
Although many have touted strategies from travel avoidance to Tamiflu to halt the spread of H1N1 flu or swine flu, a large body of evidence from the Cochrane Library suggests that concentrating on children's hygiene might be the best way to reduce the spread of respiratory illnesses.
In a town hall-style meeting at the White House on Friday, President Obama ensured Hispanic community leaders and advocates that the U.S. will not alienate the group as a result of the recent H1N1 flu outbreak believed to have started in Mexico, the AP/Las Vegas Sun reports. Obama also assured the group that they will receive treatment related to the virus regardless of legal status.
Early findings about the emerging pandemic of a new strain of influenza A (H1N1) in Mexico are published in Science.
The Centres for Disease Protection and Control (CDC) says outbreaks of the new H1N1 swine flu continue to spread across the United States and the swine influenza virus is expected to spread to all 50 states and to cause many infections ranging from mild to severe.
The latest update (# 24), from the World Health Organisation on influenza A H1N1 (swine flu) says as of the 10th May 2009, 29 countries have now officially reported cases of human infection.
The Senate Health, Education, Labor and Pensions Committee on Thursday will hold a confirmation hearing for Margaret Hamburg, President Obama's nominee for FDA commissioner, the New York Times reports.
African countries are preparing for the possibility that the H1N1 flu virus could expand in the continent, which already is experiencing epidemics of diseases such as HIV/AIDS and malaria, the AP/San Francisco Chronicle reports.
Sanofi Pasteur announced today that the U.S. Food and Drug Administration (FDA) has licensed its new influenza vaccine manufacturing facility.
President Obama has proposed a $63 billion, six-year global health initiative as part of his fiscal year 2010budget, Reuters reports (Bohan, Reuters, 5/5).
The U.S. Food and Drug Administration (FDA) today announced that it has approved a new manufacturing facility used to produce influenza virus vaccines. The facility is approved for seasonal influenza vaccine production and could be used for the production of vaccine against the new 2009 H1N1 influenza strain.
The new influenza A (H1N1), known as the swine flu, demonstrates the power of people's perceptions of risk. Sales of face masks are breaking all records not only in Mexico but also in Sweden. Hotel guests are being isolated at a hotel in Hong Kong, and people with the sniffles are being isolated in airports around the world. But before the outbreak of the flu, this was a risk that extremely few Swedes perceived as a serious threat to themselves.
For the last week or so much of the world's media has been gripped by the new influenza A H1N1 (swine flu) virus which has dominated the headlines everywhere.
Even though Australia is yet to have had any confirmed cases of influenza A H1N1 (swine flu) there has been such a demand for the anti-viral drug Tamiflu that the drug must now be rationed - it is reported that in the last week 120,000 courses of Tamiflu were sold, compared with about 10,000 courses in a normal flu season and many chemists have run out.
The World Health Organisation (WHO) says as of the 5th of May 2009, 21 countries have now officially reported 1,490 cases of influenza A (H1N1) infection (swine flu).
IBM and the University of Texas Medical Branch (UTMB) launched an effort using IBM's World Community Grid "virtual supercomputer" to allow laboratory tests on drug candidates for drug-resistant influenza strains and new strains, such as H1N1, in less than a month.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.